The present disclosure relates to compounds of the formulae herein (e.g, Formula (II)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, which are inhibitors of a
GTPase (e.g.,
cell division control
protein 42 homolog (Cdc42)). The present disclosure also provides pharmaceutical compositions comprising the compounds, pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof, and methods of treating diseases (e.g., malignant neoplastic diseases, diseases associated with aging) by administering to a subject in need thereof the compounds, pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, or prodrugs thereof.